Federated Hermes
PETX

Federated Hermes’s Aratana Therapeutics, Inc. PETX Stock Holding History

Federated Hermes’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-713
Closed -$7K – 2218
2016
Q3 		$7K Buy
+713
New +$5.92K ﹤0.01% 1885

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Federated Hermes's PETX Position: Q4 2016 in Review

Federated Hermes sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2016, closing a stake of 713 shares — an estimated $7K sold.

Federated Hermes first reported a position in PETX in Q3 2016 and held it in 1 quarter. The position peaked at $7K in Q3 2016. 107 funds tracked by Wall St. Rank hold PETX as of Q4 2016.

  • Federated Hermes reported no remaining Aratana Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Federated Hermes sold 713 Aratana Therapeutics, Inc. shares in Q4 2016, an estimated $7K.
  • Federated Hermes first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Federated Hermes's Aratana Therapeutics, Inc. position peaked at $7K in Q3 2016.
  • 107 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2016.

Based on Federated Hermes's 13F filing for Q4 2016, filed 10 Feb 2017.